[Company Logo Image] Compound validation and profiling in vitro and in vivo
Improved clinical predictability of preclinical studies
Subcutaneous and orthotopic human xenografts
Genetically modified organ specific tumour models
Receptor tyrosine kinase-driven breast cancer model

         Preclinical Concept Validation

Angiogenesis in vivo Model


Syngeneic tumour models
Pharmacokinetic studies
  Toxicology (GLP)
  Histology (Frozen Sections and Paraffin Embedded Sections)


Home Up vivoPharm Search Employment Feedback

Up Subcutaneous Orthotopic Syngeneic Angiogenesis


vivoPharmThas long-term experience in the field of angiogenesis and offers different approaches and models to study the process of neovascularisation in vivo. vivoPharm offers to study blood vessel development and blood vessel density in tissues (e.g. tumours). vivoPharmT`uses a model with a subcutaneously transplanted matrix (synthetic chamber) to attract neovascularisation. The blood vessel content in these chambers can be quantified. Therefore, this unique model represents a sophisticated tool to profile compounds with anti-angiogenic efficacy.


For price quotes please contact sales@vivoPharmTM.com


Send mail to webmaster@vivopharm.com with questions or comments about this web site.
Last modified: 18-Dec-2003